What is Immunai?
Founded in 2018 and headquartered in New York City, Immunai operates at the intersection of artificial intelligence and immunology. The company develops sophisticated AI platforms designed to decipher the complexities of the human immune system. This innovative approach aims to unlock new insights for drug discovery, disease diagnostics, and personalized medicine, positioning Immunai as a key player in the healthtech and biotech sectors. Their work is critical for advancing our understanding of immune responses and developing targeted therapeutic strategies.
How much funding has Immunai raised?
Immunai has raised a total of $295M across 3 funding rounds:
Angel/Seed
$20M
Series A
$60M
Series B
$215M
Angel/Seed (2020): $20M with participation from TLV Partners and Viola Group
Series A (2021): $60M, investors not publicly disclosed
Series B (2021): $215M supported by 8VC, Talos, Koch Disruptive Technologies, and Alexandria Venture Investments
Key Investors in Immunai
8VC
8VC is a venture capital firm known for investing in early-stage technology companies, often with a focus on deep technology and disruptive innovations.
Koch Disruptive Technologies
Koch Disruptive Technologies is an investment arm focused on funding transformative technologies and innovative solutions that have the potential to reshape industries.
Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that typically invests in companies within the life sciences and technology sectors, supporting innovation and growth.
What's next for Immunai?
With the recent influx of major enterprise-level funding and a significant strategic investment, Immunai is well-positioned for accelerated growth and innovation. The company is expected to leverage this capital to further enhance its AI capabilities, expand its research and development initiatives, and potentially forge new strategic partnerships within the pharmaceutical and biotechnology industries. This backing signals strong investor confidence in Immunai's mission to revolutionize immune system analysis and its potential impact on future healthcare solutions.
See full Immunai company page
